GlassScriptPhysician profile
Anna H Douglass
NPI 1609502327
$2,903.78
in general payments reported to CMS, 2019-2025
20 companies · $917 in 2025
The $917 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $249 · 2023: $1,106 · 2024: $632 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,524 · Education: $97.99 · Honoraria: $32.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,524.19 |
| Education | $97.99 |
| Honoraria | $32.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $475.55 | 2023-2025 | Acthar |
| Tarsus Pharmaceuticals, INC. | $399.86 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $361.06 | 2022-2025 | Clareon, Clareon Panoptix Pro, Argos |
| Bausch & Lomb Americas INC. | $276.20 | 2022-2025 | Infuse, Miebo, Xiidra |
| Oyster Point Pharma, INC. | $264.05 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Dompe US, INC. | $193.40 | 2023-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $153.82 | 2023-2025 | Cequa |
| Coopervision INC. | $123.69 | 2024 | Myday Contact Lens |
| Optos, INC. | $121.19 | 2022 | |
| Abbvie INC. | $102.15 | 2023-2025 | Vuity, Lumigan |
| Rxsight INC | $80.74 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Biotissue Holdings INC. | $57.89 | 2023-2025 | |
| Harrow Eye, LLC | $55.87 | 2025 | Vevye |
| Apellis Pharmaceuticals, INC. | $51.57 | 2025 | |
| Sandoz INC. | $50.36 | 2024-2025 | Cimerli |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $34.86 | 2025 | Iluvien, Yutiq |
| Horizon Therapeutics Plc | $34.05 | 2023 | Tepezza |
| Coherus Oncology, INC. | $23.99 | 2023 | |
| Alimera Sciences, INC. | $23.54 | 2022 | |
| Astellas Pharma US INC | $19.94 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Douglass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.